Definium Therapeutics, Inc. (DFTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Definium Therapeutics, Inc. (DFTX) has a cash flow conversion efficiency ratio of -0.126x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.89 Million) by net assets ($332.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DFTX equity to assets ratio to measure how much of total assets are equity-financed.
Definium Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Definium Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check DFTX cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Definium Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Definium Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Meshek Energy-Renewable Energies Ltd
TA:MSKE
|
0.010x |
|
Sumec Corp Ltd
SHG:600710
|
0.041x |
|
Aker Solutions ASA
OL:AKSO
|
0.124x |
|
Cisarua Mountain Dairy Tbk PT
JK:CMRY
|
0.082x |
|
Basic Fit NV
AS:BFIT
|
0.963x |
|
Computer Age Management Services Limited
NSE:CAMS
|
0.028x |
|
Construcciones y Auxiliar de Ferrocarriles S.A.
MC:CAF
|
0.141x |
|
Afi Properties Ltd
TA:AFPR
|
0.014x |
Annual Cash Flow Conversion Efficiency for Definium Therapeutics, Inc. (2015–2025)
The table below shows the annual cash flow conversion efficiency of Definium Therapeutics, Inc. from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Definium Therapeutics, Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $332.33 Million | $-131.56 Million | -0.396x | -20.79% |
| 2024-12-31 | $241.45 Million | $-79.13 Million | -0.328x | +60.22% |
| 2023-12-31 | $78.13 Million | $-64.36 Million | -0.824x | -147.95% |
| 2022-12-31 | $150.92 Million | $-50.14 Million | -0.332x | -9.96% |
| 2021-12-31 | $151.66 Million | $-45.82 Million | -0.302x | +2.86% |
| 2020-12-31 | $75.87 Million | $-23.60 Million | -0.311x | -309.18% |
| 2019-12-31 | $2.74 Million | $-208.12K | -0.076x | +62.91% |
| 2018-12-31 | $3.52 Million | $-722.45K | -0.205x | -21.47% |
| 2017-12-31 | $3.95 Million | $-665.98K | -0.169x | +19.37% |
| 2016-12-31 | $127.28K | $-26.64K | -0.209x | -27.73% |
| 2015-12-31 | $284.17K | $-46.56K | -0.164x | -- |
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a cli… Read more